Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Become EABM
Become Reviewer

Abstract Ahead of Print

Fas Ligand Enhances Apoptosis of Human Lung Cancer Cells Cotreated with RIG-I-Like Receptor Agonist and Radiation

Volume:20
Yoshiaki Sato, Hironori Yoshino*, Eichi Tsuruga and Ikuo Kashiwakura

Use of small-molecule inhibitory compound of PERK-dependent signaling pathway as a promising target-based therapy for colorectal cancer

Volume:20
Wioletta Rozpędek, Dariusz Pytel, Adam Wawrzynkiewicz, Natalia Siwecka, Adam Dziki, Łukasz Dziki, J. Alan Diehl and Ireneusz Majsterek*

Hypermethylation of single CpG dinucleotides at the promoter of CXCL13 gene promote cell migration in cervical cancer

Volume:20
Dong Ma , Shao-Bei Fan , Na Hua, Guo-Hua Li, Quan Chang and Xiao Liu *

Idronoxil as an Anticancer Agent: Activity and Mechanisms

Volume:20
Kate Porter*, W. Douglas Fairlie, Olivier Laczka, Frederic Delebecque and John Wilkinson

Disintegrin tablysin-15 suppresses cancer hallmarks in melanoma cells by blocking FAK/Akt/ERK and NF-κB signaling

Volume:20
Zhenhui Deng, Qingye Zeng, Jinwei Chai, Bei Zhang, Wenhong Zheng, Xueqing Xu and Jiguo Wu*

Old and New Approaches to Target the Hsp90 Chaperone

Volume:19
Jackee Sanchez, Trever R. Carter, Mark S. Cohen* and Brian S. Blagg

circEPSTI1 acts as a ceRNA to regulate the progression of osteosarcoma

Volume:19
Xinyu Tan, Duxun Tan, Haomiao Li, Ye Lin, Zhishen Wen and Canjun Zeng*